Peptide
PT-141 / Bremelanotide (Peptide)
PT-141 (bremelanotide) is FDA-approved as Vyleesi and represents one of the few treatments that actually works on the brain chemistry of sexual desire rather than just physical blood flow. Clinical trials show it significantly increases sexual desire in women, though about 40% experience nausea that typically decreases with repeated use. While most studies focused on younger women with hypoactive sexual desire disorder, this medication offers a genuine option for women whose desire has disappeared during menopause.
30-second summary
PT-141 (bremelanotide) is FDA-approved as Vyleesi and represents one of the few treatments that actually works on the brain chemistry of sexual desire rather than just physical blood flow. Clinical trials show it significantly increases sexual desire in women, though about 40% experience nausea that typically decreases with repeated use. While most studies focused on younger women with hypoactive sexual desire disorder, this medication offers a genuine option for women whose desire has disappeared during menopause.
low libido — strongsexual satisfaction — strong
Overall: Strong evidence
Randomised controlled trials
Multiple randomized controlled trials show PT-141 significantly increases satisfying sexual events and sexual desire scores compared to placebo.
Real-world data confirms effectiveness in clinical practice with similar response rates to trials.
Systematic reviews confirm consistent benefit across studies with manageable side effect profile.
Menopause-specific trials
Very limited data exists specifically for menopausal women, though the mechanism suggests it should work regardless of hormone status.
What we do not know
We don't know the optimal dosing specifically for postmenopausal women, as most trials studied premenopausal women aged 18-50. We lack data on how it interacts with hormone replacement therapy or how effectiveness changes with age-related brain chemistry shifts. Long-term safety data beyond 24 weeks of use is not available. We don't know if the 40% nausea rate differs in older women or those on multiple medications.
How it is used
Common dose range
As prescribed — typically 1.75mg self-administered subcutaneously before anticipated sexual activity
Notes on dosing
Requires a prescription. FDA-approved for HSDD in premenopausal women — use in postmenopausal women is off-label. Discuss with a sexual health specialist.
Get it from food first
Food sources are better absorbed than most supplements and come with co-factors that support the same pathways. If you eat two or three of these consistently, you may not need a supplement at all.
What depletes PT-141 / Bremelanotide (Peptide)
Not applicable - PT-141 is a synthetic peptide medication, not a nutrient that can be depleted by diet.
Interactions and cautions
No significant interactions noted at recommended doses.
Rose bottom line
"This is one of the few medications that actually targets desire itself rather than just treating the mechanics, and it works for many women who thought their libido was gone forever. Yes, the nausea is real and significant, but it often improves with time. Talk to your doctor about whether this prescription option makes sense for your situation."